Breakthrough in Cancer Cell Screening Advances Personalised Treatment of Childhood Leukaemia


Acute Lymphoblastic Leukaemia Awareness RibbonAcute Lymphoblastic Leukaemia is the most common form of childhood cancer, but thanks to research, up to nine in 10 children diagnosed with ALL will now achieve a long-term cure. Unfortunately, in those whose disease relapses, the prognosis is not that good and fewer than 6 in 10 children survive longer than 5 years.

Researchers at Newcastle University have recently completed the largest study of its kind, and thanks to their findings, doctors will now be able to analyse the genetic profile of cancer cells to personalise treatment and improve survival rates.

The Newcastle study, Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukaemia, published in the prestigious journal Blood, analysed leukaemia cells from 427 children treated for relapsed Acute Lymphoblastic Leukaemia between 2003 and 2013, using a variety of genetic tests including fluorescence in situ hybridisation (FISH), where glowing tags are bound to sequences of DNA within the cancer cells, allowing scientists to view specific genetic changes under a microscope.

Genetic faults within developing white blood cells kick-start and drive leukaemia growth. The types and combinations of genetic errors are known to influence whether a child is likely to respond well to initial treatment, which in turn affects whether they have a good or poor chance of survival.

Genetic screening is already used to tailor treatment at diagnosis, ensuring children receive the most appropriate intensity of chemotherapy. Until now it has not been fully understood how these ‘genetic markers’ can be used to guide treatment if the leukaemia returns.

Currently, children with relapsed leukaemia are grouped by whether they were at a standard or high risk of a poor outcome, based on factors such as how long the child had been in remission and if leukaemia cells were present in the bone marrow at the time of relapse or not. Patients currently deemed to be high risk under these criteria will undergo a stem cell transplant, while standard risk patients are generally treated with more chemotherapy.

Patients whose leukaemia returns a long time after treatment has ended have, up until now, been thought to have a good chance of survival and generally receive less intense chemotherapy than patients thought to be at higher risk.

The team, led by Professor Anthony Moorman and Dr Julie Irving from the Northern Institute for Cancer Research at Newcastle University found that children in the standard risk group who, at the time of relapse, had one or more ‘high risk’ genetic abnormalities responded poorly to chemotherapy.

The researchers also discovered abnormalities in a number of genes (e.g. TP53, NR3C1, BTG1 and NRAS), which not only provided additional information about how and why these children responded poorly to current therapy, but also provided useful insights into how future children with similar gene defects might be more efficiently treated. For example, children with a defect in one of the RAS genes may benefit from a new drug called a ‘MEK inhibitor’, which specifically kills cells with a faulty RAS gene.

Anthony Moorman, Professor of Genetic Epidemiology, who co-leads the Leukaemia Research Cytogenetics Group at Newcastle University, said:

Current methods used to guide treatment for relapsed leukaemia are not accurate enough, with some children believed to have a good chance of survival actually responding very poorly to chemotherapy. Screening patients at relapse for key genetic abnormalities that influence outcome will ensure that treatment can be personalised, thereby improving their chances of survival.

The researchers also identified a large group of children with ‘low risk’ genetic faults. When these children also had good clinical risk factors – such as a long first remission – their response to standard chemotherapy was very good and they could be spared a stem cell transplant.

Dr Alasdair Rankin, Research Director at Bloodwise, said:

The outlook for children who relapse is generally poor and so more effective treatment approaches are desperately needed. These findings represent a significant step forward in the development of personalised treatment for these patients. Further research will be needed to test whether tailoring treatment for relapsed disease based on genetic factors does actually improve survival rates.”

 

Advertisements

About LFCT

This is a blog about CHILDHOOD CANCER and CHILDHOOD CANCER AWARENESS Little Fighters Cancer Trust is a non-profit organisation that offers support and aid to Children with Cancer and their families. When a child is diagnosed with cancer it affects the whole family. One of the parents, usually the mother, must give up their job to care for the child and this creates financial problems for the family. In South Africa especially the majority of these families are not well-to-do; many of them are rural. A diagnosis of cancer can wipe out any family’s finances, let alone a poor family. The costs of special medications, special diets, hospital stays, transport to and from the hospital or clinic and accommodation and food costs for the mother who spends most of the time at her child’s bedside are astronomical. These are the people and problems that fall through the cracks, and these are the people that Little Fighters Cancer Trust has pledged to help in any way possible. LFCT takes a holistic approach to assisting the Children with Cancer and their Families, with the main aim to be the preservation of individual dignity and pride. Little Fighters Cancer Trust also focuses on promotion and advocacy of National Childhood Cancer Awareness in an effort to increase awareness of Early Warning Signs of Childhood Cancer. This would result in earlier diagnosis, giving the Child with Cancer more of a chance at Treatment and Survival. See "About" for more Background info

Posted on 26 August, 2016, in Blog, Cancer Treatments, Medical Treatments, Research and tagged , , , , , , , , , , , , . Bookmark the permalink. Leave a comment.

Please help us to Raise Childhood Cancer Awareness by Commenting and Sharing

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

My Name is Chuma

a blog from a Cape Town inner city artist

Knitting Rays of Hope

Spreading Hope...a hat at a time.

The Starlit Path

An African Travelling Under Starry Skies

Soul Gatherings

Spiritual Moments in the Human Experience

lovehopeandcourage

Inspired by ordinary people doing extraordinary things

Surviving The Bubble

Jamie Hutchings, Public speaker, leukemia survivor and depression fighter

beingmommie.com

Sharing my learnings of being a mother

Art of Social Work

Kristina Sargent

How to Provide

for your family

%d bloggers like this: